Single-Molecular Heteroamyloidosis of Human Islet Amyloid Polypeptide

Subscriber access provided by Stockholm University Library

Communication

Single-molecular hetero-amyloidosis of human islet amyloid polypeptide Aleksandr Kakinen, Yanting Xing, Nuwan Dhanushka Hegoda Arachchi, Ibrahim Javed, Lei Feng, Ava Faridi, Alon M. Douek, Yunxiang Sun, Jan Kaslin, Thomas P. Davis, Michael J Higgins, Feng Ding, and Pu Chun Ke Nano Lett., Just Accepted Manuscript • DOI: 10.1021/acs.nanolett.9b02771 • Publication Date (Web): 28 Aug 2019 Downloaded from pubs.acs.org on August 29, 2019

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

Single-molecular hetero-amyloidosis of human islet amyloid polypeptide

Aleksandr Kakinen,1 Yanting Xing,2 Nuwan Hegoda Arachchi,3 Ibrahim Javed,1 Lei Feng,3 Ava Faridi,1 Alon M. Douek4, Yunxiang Sun,2,5 Jan Kaslin4, Thomas P. Davis,1,6* Michael J. Higgins,3* Feng Ding2* and Pu Chun Ke1*

1ARC

Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of

Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia 2Department 3ARC

of Physics and Astronomy, Clemson University, Clemson, SC 29634, USA

Centre of Excellence for Electromaterials Science, University of Wollongong, Innovation Campus, Squires Way, NSW 2522, Australia

4Australian

Regenerative Medicine Institute, Monash University, 15 Innovation Walk, Clayton, VIC 3800, Australia 5Department

6Australian

of Physics, Ningbo University, Ningbo, Zhejiang 315211, China

Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia

Corresponding Authors Email: Thomas P. Davis : [email protected]; Michael Higgins: [email protected]; Feng Ding: [email protected]; Pu Chun Ke: [email protected]. Phone: +61-03-99039260; +61-02-42213989; +1-864-6560459 ; +61-03-99039267

1 ACS Paragon Plus Environment

Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ABSTRACT Human amyloids and plaques uncovered post mortem are highly heterogeneous in structure and composition, yet literature concerning the hetero-aggregation of amyloid proteins is extremely scarce. This knowledge deficiency is further exacerbated by the fact that peptide delivery is a major therapeutic strategy for targeting their full-length counterparts associated with the pathologies of a range of human diseases, including dementia and type 2 diabetes (T2D). Accordingly, here we examined the co-aggregation of full-length human islet amyloid polypeptide (IAPP), a peptide associated with type 2 diabetes, with its primary and secondary amyloidogenic fragments 19-29 S20G and 8-20. Single-molecular aggregation dynamics was obtained by high-speed atomic force microscopy, augmented by transmission electron microscopy, X-ray diffraction and super-resolution stimulated emission depletion microscopy. The co-aggregation significantly prolonged the pause phase of fibril elongation, increasing its dwell time by threefold. Surprisingly, unidirectional elongation of mature fibrils, instead of protofilaments, was observed for the co-aggregation, indicating a new form of tertiary protein aggregation unknown to existing theoretical models. Further in vivo zebrafish embryonic assay indicated improved survival and hatching, as well as decreased frequency and severity of developmental abnormalities for embryos treated with the hetero-aggregates of IAPP with 1929 S20G, but not with 8-20, compared to the control, indicating the therapeutic potential of 1929 S20G against T2D.

KEYWORDS.

IAPP · fragment · hetero-aggregation · high-speed atomic force

microscopy · fibrillization dynamics


Page 2 of 28

Page 3 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

Amyloid fibrils are highly organized filamentous aggregates of peptides and proteins.1 First observed clinically in Alzheimer’s disease (AD), Parkinson’s disease (PD) and type 2 diabetes (T2D) patients, amyloid fibrils share a common characteristic in possessing dense stacks of βstrands stabilized by hydrogen bonds along the fibril axis.2 Each amyloid fibril typically consists of two or more protofilaments of β-sheets stretching over the length scale of micrometers, self-assembled by hydrophobic interactions. Amyloid fibrils are polymorphic mesoscopically, assuming versatile forms of twisted ribbons, helical ribbons, nanotubes or flat tapes up to tens of nanometers in diameter depending on the sequence of the amyloid protein, ionic strength, and aggregation time.3 The aggregation of amyloid proteins can be directly observed or inferred from transmission electron microscopy (TEM), X-ray diffraction, circular dichroism spectroscopy, Fourier transform infrared spectroscopy, atomic force microscopy (AFM),4-12 as well as nuclear magnetic resonance spectroscopy. The kinetics of amyloid protein aggregation, when probed by a thioflavin T (ThT) or Congo red fluorescence assay, follows a sigmoidal trajectory to indicate the three stages of (primary and secondary) nucleation,13-14 elongation and saturation, where disordered monomers aggregate to render α-helical and then β-sheet-rich oligomers, protofibrils, amyloid fibrils and plaques. While amyloid fibrils and plaques may take decades to form in vivo due to modulation by chaperone proteins, metal ions, pH and other structural and physiological factors , amyloid proteins can rapidly transform in vitro from functional monomers to fibrils within days (e.g., amyloid beta/Aβ and alpha synuclein/αS, whose aggregation is a hallmark of AD and PD, respectively),15-17 or hours (e.g., human islet amyloid polypeptide/IAPP, whose aggregation is associated with T2D).18-19 Amyloidosis is a hallmark of a range of debilitating neurological disorders and metabolic diseases. Accordingly, much research over the past two decades has been devoted to understanding the aggregation of amyloid proteins and their elicited toxicity. Towards 3 ACS Paragon Plus Environment

Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

therapeutic implementations, the design and delivery of peptides,20 metal ions,21-23 monoclonal antibodies,24-26 small molecules4,

27-30

and, more recently, various nano- and polymeric

materials18, 31-44 to target amyloid proteins has become a significant area of research. However, these efforts are overshadowed by a lack of cure for amyloid diseases, highlighting a crucial need for additional research and development of new strategies against amyloidosis. Human IAPP is one of the most aggregation-prone peptides known. It has been established that the residues 20-29 of human IAPP are highly amyloidogenic and cytotoxic.45-47 Serine-toglycine substitution at position 20 (S20G), a familial mutation implicated in the onset of T2D mellitus in the Japanese population, results in increased amyloidogenicity and cytotoxicity of IAPP.48-49 In contrast, a single-point mutation at residue 26 from isoleucine to proline converted IAPP into a potent fibrillization inhibitor.50 It has also been found that fibrils formed from the 19-29 S20G fragment are structurally similar to that of full-length human IAPP and hence may serve as a model for studying the toxicity of the latter.19 In addition to the residues 19-29, a secondary amyloidogenic domain of human IAPP was identified between residues 8 to 20.51-52 While human amyloid fibrils and plaques are highly heterogeneous in structure and composition,1, 28, 53 data on hetero-amyloidosis remains extremely scarce. Much of the research in the field of amyloidosis has been conducted for single amyloid proteins that have limited applicability to in vivo conditions. The need for understanding hetero-amyloidosis is further warranted by peptide-based therapeutics, a major strategy for targeting toxic oligomeric or fibrillar amyloid proteins through a sequence-dependent specificity between the delivered peptide and the host. Accordingly, here we examined the co-aggregation of full-length human IAPP with its fragments IAPP 19-29 S20G and 8-20. In addition to the use of TEM and a ThT kinetic assay, high-speed atomic force microscopy (HS-AFM) at a scanning rate of 0.5 frame/sec was employed to record IAPP self-assembly and co-aggregation with its two major amyloidogenic fragments. This technique enabled the aggregation dynamics of IAPP to be 4 ACS Paragon Plus Environment

Page 4 of 28

Page 5 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

revealed in real-time and at single-molecule resolution, providing information regarding the nature of IAPP hetero-amyloidosis that is unavailable from ensemble methods such as the ThT kinetic assay. Our data indicated that hetero-aggregation retarded fibril elongation but increased aggregation rate of IAPP, and altered IAPP fibril flexibility. Surprisingly, coelongation of single and bundled IAPP fibrils, but not protofilaments, was observed for IAPP co-aggregating with 19-29 S20G or 8-20, a phenomenon unaccounted for by existing theoretical models.54-57 Notably, an in vivo zebrafish embryonic assay revealed significant amelioration of IAPP toxicity due to hetero-aggregation of the peptide with 19-29 S20G, but not with 8-20. Together, this study provided first insights into hetero-aggregation down to single fibrillar and sub-second levels, as well as its biological implications which are crucial for the development of peptide-based therapeutics against T2D.

The effects of the amyloidogenic fragments on the aggregation kinetics, mesoscopic and atomic structures of full-length IAPP were examined using a ThT kinetic assay, TEM, stimulated emission depletion (STED) microscopy, HS-AFM, single-crystal X-ray diffraction (XRD) and discrete molecular dynamics (DMD) computer simulations (Scheme 1). Specifically, IAPP fibrillization in the presence and absence of the 11-residue 19-29 S20G (Ser20 replaced by Gly) and the 13-residue 8-20 IAPP fragments (Fig. 1A) was characterized to derive new insights into IAPP hetero-amyloidosis. ThT kinetics assay on IAPP-fragment co-aggregation. The ThT assay indicated that 19-29 S20G significantly accelerated IAPP aggregation (Fig. 1B). Specifically, even at a low fragment/IAPP molar ratio (1:5) the nucleation (lag) time of 25 µM IAPP was noticeably reduced from 6.1±0.4 h to 2.6±0.9 h (Fig. 1D). Further increases of the fragment/IAPP ratio to 1:1 and 2:1 decreased the nucleation time to 2.4±0.2 h and 1.9±0.8 h, respectively.


Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

In addition, the ThT fluorescence intensity in the saturation phase of IAPP co-fibrillated with 19-29 S20G was up to 50% lower than that of 25 µM IAPP (Fig. 1B). A similar observation was reported by Westermark et al. for full-length IAPP S20G vs. full-length wide-type IAPP.58 Moreover, in contrast to full-length IAPP, no concentration-dependent increase in total ThT fluorescence was observed for hetero-aggregation. TEM analysis revealed that amyloid fibrils that formed in the presence of 19-29 S20G had markedly different morphology from the IAPP control (Fig. 2B vs. 2A). Specifically, the fibrils in the presence of the fragment appeared to be highly twisted soft helical ribbons58 (Fig. 2B) with altering periodicities of 100-370 nm (Table S1, Supporting Information). In contrast, pure IAPP displayed rich polymorphism of mature amyloids (Fig. 2A). Moreover, the twisted fibrils of pure IAPP were found to have a uniform periodicity of 110 ± 17 nm, and a 4× longer persistence length than amyloids formed in the presence of 19-29 S20G (Table S1). This greatly elevated flexibility of IAPP fibrils in the presence of 19-29 S20G may imply pathogenic consequences in the context of T2D, an aspect to be examined in future in vivo studies. The 8-20 fragment accelerated IAPP aggregation near the efficiency of its cognate full-length peptide (Figs. 1C&D). Similarly to 19-29 S20G, co-fibrillization of IAPP with 8-20 had no clear concentration-dependent effect on the ThT fluorescence at saturation. This can be attributed to the fact that no increase in ThT fluorescence was observed for 19-29 S20G and 820 aggregated at 1 mM while fibrils were seen with TEM (data not shown). Similarly, the fibrillization of fragment 8-20 in the literature was mainly characterized by AFM, X-ray diffraction, or TEM.52,

59-60

Hence the ThT assay, while informative for probing peptide

aggregation kinetics, may not accurately reflect the total β-sheet content in IAPP heteroaggregates. Interestingly, in contrast to the 19-29 S20G, twisted IAPP amyloid fibrils formed in the presence of the 8-20 fragments were 70% more rigid than the control, while non-twisted fibrils were 18% more rigid compared to pure IAPP aggregates (values of persistence length 6 ACS Paragon Plus Environment

Page 6 of 28

Page 7 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

see Table S1). However, the overall polymorphism of IAPP fibrillated in the presence of the 8-20 fragments (Fig. 2C) was comparable to that of pure IAPP (Fig. 2A). Aβ16-22, a short Aβ fragment between residues 16-22 that was shown to inhibit fibril formation of full-length Aβ1-42 and thus proposed to be a therapeutic agent for the treatment of AD,61-63 had little effect on IAPP aggregation (Fig. S1), in contrast to 19-29 S20G and 820. This indicates that 19-29 S20G and 8-20 were more selective over Aβ16-22 towards binding to their complementary regions of full-length IAPP. Structural analyses of IAPP-fragment co-aggregation. STED microscopy confirmed that both 19-29 S20G and 8-20 co-aggregated with full-length IAPP to form hetero-peptide amyloid fibrils (Figs. 2D-I). The presence of amyloid fibrils was confirmed using β-sheet sensitive ThT dye (Figs. 2D-F), and super-resolution STED microscopy (spatial resolution: 20 nm; an order or magnitude higher than confocal fluorescence microscopy) verified the presence of Alexa 647-labelled 19-29 S20G (Fig. 2H) and 8-20 (Fig. 2I) segments inside the fibrils. XRD revealed the signature pattern of amyloid fibrils, at 4.7 Å for inter-strand spacing and 8–10 Å for intersheet distance, which was not affected by hetero-aggregation with the fragments (Figs. 2J-L). The greater flexibility of IAPP + 19-29 S20G and increased rigidity of IAPP + 8-20 compared to IAPP control, based on their values of persistence length (Table S1), can be explained by a proposed model of fragment binding to full-length IAPP according to the complementarity of amino-acid sequences (Figs. 2M-O). As the 19-29 S20G residues were buried in the interior of a double U-shaped IAPP fibril (highlighted in orange color in Figs. 2M&2N), the segments bound the corresponding sections of cognate full-length IAPP to alter the fibrillar morphology of the resulting hetero-aggregates (Fig. 2R vs. 2P). In contrast, the outer binding sites of 8-20 segment (Figs. 2O&2S) did not dramatically change the fibril contour.


Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Multiscale discrete molecular dynamics simulations of IAPP-fragment co-aggregation. We performed both atomistic and coarse-grained (CG) DMD simulations to gain a molecular insight into the effects of different amyloidogenic peptide fragments on IAPP aggregation and fibrillization. Using all-atom simulations, IAPP dimerization was studied in the absence or presence of equimolar fragments. In the mixture, fragments 19-29 S20G remained predominately as coils while fragments 8-20 were helical (Fig. S2A inset and Fig. S2B). Compared with the IAPP dimer control, the presence of 19-29 S20G or 8-20 fragment increased the β-sheet content of IAPP in the primary amyloidogenic region (i.e., residues 22-29) (Fig. S2A). The presence of 19-29 S20G also increased the β-sheet content and reduced the helical content of IAPP in the N-terminus (especially, residues 8-16), but the helical 8-20 increased the helical propensity of IAPP in the same region. The all-atom simulations indicated that 820 encountered a higher energy barrier associated with helix unfolding than 19-29 S20G (Fig. S2) towards aggregation. The conformation of IAPP monomers and dimers were well studied in prior computational simulations.64-69 Although secondary structure contents were force filed dependent, IAPP mainly adopted unstructured conformations with some helical structure in the N-terminal and transient β-sheet structures in amyloidogenic core region (IAPP 8-20 and IAPP 19-29),64-69 our all-atom DMD simulations are consistent with those previous simulation studies. For example, residues around A8-F15 displayed greater propensities to form helices than the rest region of IAPP and weakly populated β-sheet structures were mainly formed by residues around L16S28, which was consistent with previous IAPP dimer simulation studies.67-69 To capture the hetero-fibrillization process, we performed CG DMD simulations with peptide models possessing low, intermediate and high energy barriers between aggregate-incompetent (π) and competent (β) states to represent IAPP, 19-29 S20G and 8-20, respectively (Fig. 1E,


Page 8 of 28

Page 9 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

Methods in the Supporting Information). Starting from isolated peptides in the π-state the time evolution of the total number of peptides forming β-sheets was computed for the different molecular systems to mimic the ThT assay (Fig. 1F). Indeed, IAPP + IAPP (refers to as double IAPP concentration) and IAPP + 19-29 S20G displayed similar lag times and elongation rates, while IAPP + 8-20 rendered a longer lag time than IAPP + IAPP. This is consistent with the ThT assay showing that 19-29 S20G accelerated IAPP aggregation more efficiently than 8-20 (Figs. 1B-D). High-speed atomic force microscopy (HS-AFM) and in silico evidence of retarded and unidirectional IAPP co-elongation. It is important to note that ensemble aggregation kinetics represents a convolution of protein nucleation, elongation and dissociation70 and does not accurately discern the presence of amyloid fibrils until the latter reach a threshold in quantity.71 Accordingly, we further examined the effects of the fragments on IAPP fibril formation using a single-fibril elongation assay. Namely, HS-AFM was utilized to monitor the effects of the two types of fragments on single IAPP fibril elongation (Figs. 3&4; videos S1-S3, for the elongation of IAPP, IAPP + 19-29 S20G, and IAPP + 8-20, respectively). Similar to the observation by TEM, HS-AFM analysis (Fig. 3A) confirmed that pure IAPP fibrils possessed different morphologies and various height profiles between 9 and 20 nm (Figs. 3D,E), suggesting predominant formation of mature higher-order fibrils despite the presence of the mica substrate. Moreover, we observed a convergence of fibril morphologies resulting from the co-aggregation of IAPP with the 19-29 S20G fragment (Fig. 3B). Fibril heights of 9 ± 1.7 nm (an accurate representation of fibril width due to the finite tip size, which renders the lateral sizes in AFM images to appear larger due to tip “broadening”) were recorded by HS-AFM (Figs. 3D,F), corresponding to fibrils assembled from 2 to 3 protofilaments (Figs. 3K-M). In addition, enhanced surface roughness resulted from the formation of small aggregates (Figs. 3B,F). A similar phenomenon was observed for IAPP co-aggregation with the 8-20 fragment 9 ACS Paragon Plus Environment

Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(Figs. 3C,G); however, the overall fibril polymorphism was comparable to the control, as indicated by the various height profiles of the fibrils (Fig. 3D,G). Analysis of fibril kymograph projections (Figs. 3H-J and Figs. S3,S4) revealed that the elongation rates of fibrils coaggregated with the fragments were slower than the self-assembly of full-length IAPP (Fig. 4A). The elongation rate constant (E) of 1 µM IAPP was 0.52 ± 0.19 nm/s, whereas it was 0.12 ± 0.07 nm/s and 0.10 ± 0.03 nm/s in the case of IAPP (0.5 µM) co-aggregated with the 19-29 S20G and 8-20 fragments (0.5 µM), respectively. Surprisingly, co-elongation of multiple mature IAPP fibrils was observed (Figs. 3K-M; video S4), indicating a new form of tertiary protein aggregation driven by H-bonding between the cooperating fibrils. The bending of the bundled fibrils may result from accumulative mismatches between the elongation rates of the fibril constituents over time, which is consistent with the TEM observations (Fig. 2B). The measured elongation rate for full-length IAPP at a concentration of 1 µM was comparable to that of IAPP1-37 (16 and 40 nm/min,72 concentration: 2 µM) and Aβ1-42 (0.4-2.5 nm/s, concentration: 2.5 µM in 10 mM phosphate) obtained with HS-AFM,73 and slower than the elongation of Aβ25-35 (5-100 nm/s, concentration: 10-50 µM) determined by scanning-force kymography.74 Consistent with the observation by Huang et al.,72 we recorded predominantly uni-directional elongation of IAPP fibrils in both self and hetero-aggregation (Fig. S5), also in agreement with other studies reporting fast- and slow-growing ends of amyloid fibrils.73-76 Similar to previous HS-AFM74,

77

and total-internal-reflection fluorescence microscopy76

studies of αS and Aβ, we noticed the intermittent nature of IAPP elongation dynamics (Figs. 3H-J and Fig. S4). Intermittent elongation of amyloid fibrils, or pausing, has been proposed in the literature as consequential to the addition of a kinetically trapped state at the fibril end that is off pathway from the normal monomer-to-fibril addition reaction.76


Page 10 of 28

Page 11 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

We also monitored the growth of single fibrils in CG simulations by tracking the time evolution of the number of peptides in a given fibril (Fig. 4B). The fibril growth exhibited a similar intermittent increase in silico (referring as the elongation state and pause state noted by line arrow and dash arrow in Fig. 4B, respectively) as fibril traces shown in Fig. S4A. Examination of the simulation trajectory (Fig. S6) indicated that the heterogeneous distribution of soluble peptides resulted in these two states during fibrillization. During the elongation phase, there were a locally high concentration of monomeric peptides around the tracked fibril (highlighted in Fig. S6 on the left) and a locally low concentration of peptides near the fibril in the pause phase (highlighted in Fig. S6 on the right). By analyzing the growth of multiple fibrils from independent simulations, the apparent elongation rates were obtained for IAPP control and IAPP mixed with the fragments (Fig. 4D), with typical fibril structures shown as insets. Consistently with the experimental elongation assay (Fig. 4A), the elongation rate for IAPP self-assembly was higher than IAPP co-aggregated with fragments from the simulations. In addition, co-aggregation of IAPP with the fragments significantly prolonged the pause phase of fibril elongation, increasing its dwell time from 53 ± 32 s to 188 ± 127 s and 156 ± 136 s in the presence of the 19-29 S20G and 8-20 fragments, respectively (Fig. 4E). This phenomenon may arise from the incorrect docking of either the fragments alone or monomer-fragment complexes to the end of an elongating protofibril, which was then followed by dissociation of the ‘faulty’ fragment/complex or a conversation of the latter into the elongation-competent conformation. Notably, pure IAPP elongation intermittence arose from the same scenarios, and escape from this metastable state would require a transition across an energy barrier either from the trapped state to the correct conformation state, or to the monomeric state. Our observations suggest that the energy barriers of this trapped state were higher in the case of heretoaggregation. This is consistent with the study by Laurence et al. of Aβ1-42 elongation at different temperatures, where increased temperature (higher free energy) decreased the fraction


Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

of time that a fibril end spent in the pause state.76 Although we did not observe statistically significant differences in the step time (Fig. 4F), we did find that the step size was shortened in the case of IAPP co-aggregation with 8-20 fragments (Fig. 4G). Interestingly, there was a strong correlation between the step size and step time (R2 = 0.85) for the fibrillization of pure full-length IAPP (Fig. 4H). However, no such dependence was found in the presence of the fragments (R2 = 0.32 and 0.28 for IAPP + 19-29 S20G and IAPP + 8-20, respectively). Based on this observation and the fibril elongation trajectories with pause sections artificially removed (Fig. S4B), we conclude that the rate of full-length IAPP elongation was constant but their co-aggregation with the fragments varied over time, likely due to the entropic gains of the latter heterogeneous systems. Pause-free projection of fibrillization trajectories avoided underestimation of fibril elongation rate due to intermittencies (Fig. S4B). The pause-free elongation rate of IAPP was determined to be 0.99 ± 0.50 nm/s, whereas IAPP with 19-29 S20G and 8-20 fibrillated at the rate of 0.50 ± 0.32 nm/s and 0.36 ± 0.26 nm/s, respectively (Fig. 4C). According to previously reported mass-per-length (MPL) measurements (using scanning TEM, IAPP protofibrils possessed a mass of ~20 kDa/nm.53, 78-79 Similar to other amyloids, IAPP fibrils contain β-sheets with a cross-β alignment relative to the long fibril axis80 and a spacing of 4.7 Å between β-sheets strands (Figs. 2J-L).78 Thus, it is expected that the MPL of IAPP fibrils to be ƞ·MW/0.47 kDa/nm,81 where MW is the molecular weight of the peptide and ƞ the number of molecules in each β-sheet spacing. This indicates that ~2.44 IAPP monomers constituted each cross-β repeat. By assuming that fibrils elongated due to the addition of monomers to one end, we converted pause-free elongation rates to absolute elongation rates by Ea=2.44·E/0.47 monomers per second. Thus, the absolute elongation rate of pure IAPP (1 µM) was about 5.1 monomers·s-1, while co-aggregation of IAPP with 19-29 S20G and 8-20 fragments at the same total molar


Page 12 of 28

Page 13 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

concentration of monomers (1 µM) was considerably lower, at 2.6 and 1.9 monomers·s-1, respectively.

Effect of hetero-aggregation on IAPP toxicity in vivo. The use of zebrafish embryos as an in vivo model has led to remarkable progress in toxicology and genetic studies,82 and has recently been applied to the study of amyloidogenesis taking advantage of its high fecundity, well characterized developmental stages, transparency of embryos, and multicellular and multiorgan compositions.42-43,

83-85

Here an in vivo toxicity assay was performed by

microinjecting IAPP with or without 19-29 S20G and 8-20 fragments into the chorionic fluids of 2 hpf zebrafish embryos. Embryonic survival, hatching and developmental phenotypic abnormalities (such as pericardial oedema and axial curvature) were quantified in Figure 5. Both fragments exhibited negligible toxicity to the embryos compared to embryos injected with distilled water as a negative control (Fig. 5A). In addition, hatching of larvae at the expected developmental stage of 3 days post-fertilisation (dpf) was timely for both of these treatment groups (Fig. 5B), and no statistically significant level of developmental abnormalities was detected (Fig. 5C). In the case of IAPP, embryonic survival was 67 ± 9 %, hatching was notably delayed (70 ± 11 %), and the frequency of phenotypic abnormalities observed was 25 ± 16 % higher than in the control group. Hetero-aggregation with 8-20 did not mitigate IAPP toxicity (survival: 66 ± 12 %), hatching (69 ± 6 %), and a greater proportion of embryos exhibited hallmark toxicity phenotypes than those exposed to IAPP alone (46 ± 16 %). In contrast, coaggregation IAPP and 19-29 S20G increased the rate of survival of embryos relative to controls (77 ± 11 %), the hatching rate was 92 ± 14 %, and the rate of phenotypic abnormalities was comparable to the frequency observed in the control group. These findings with 19-29 S20G are reminiscent of the potency of peptide KLVFF in mitigating the aggregation and toxicity of Aβ, a major strategy developed against AD.61-63


Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Aberrant aggregation of human IAPP and amyloid deposition in the pancreas is a hallmark of T2D.86 As the amyloid fibrils formed in vivo are highly heterogeneous in composition and structure,1, 28, 53 in this work we investigated the effects of two major amyloidogenic IAPP fragments on the fibrillization kinetics, dynamics and mesoscopic structure of full-length IAPP.47 Specifically, 19-29 S20G elevated the flexibility, retarded the elongation (both elongation rate and dwell time) and altered the morphology of IAPP fibrils. In contrast, the secondary amyloidogenic IAPP domain 8-20 retarded the elongation (both elongation rate and dwell time), reduced fibrillar flexibility, but had little impact on the IAPP morphology. Previous literature has shown that the mechanical properties of amyloid fibrils are related to their steric zipper patterns.87 We propose that co-aggregation with the fragments induced defect sites within IAPP fibrils (Figs. 2M-O). Furthermore, it has been previously shown that fibrils formed from the 19-29 S20G fragment were structurally related to that of full-length IAPP and comprised the spine of the mature fibrils.19 Here we further revealed that hetero-amyloidosis altered not only the final mesoscopic structure and mechanical property of the amyloid fibrils but also the elongation process itself. Furthermore, we also demonstrated that heteroaggregation with 19-29 S20G can alter the toxicity profile of IAPP in vivo. Together, these observations have provided valuable new insights into the heterogeneity, complexity and dynamics of protein aggregation on the single-molecule and sub-second levels. This new knowledge of hetero-amyloidosis may prove beneficial for developing alternative strategies in the mitigation and prevention of T2D and other amyloid diseases.88


Page 14 of 28

Page 15 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

Supporting Information Experimental methods. Table S1 of persistence length and periodicity of IAPP fibrils in the presence or absence of 19-29 S20G or 8-20 fragments. Atomic simulation analysis, image analysis method for kymograph, rates of elongation for IAPP with or without the fragments, time-lapse videos compiled from HS-AFM imaging and simulated fibril elongation and dwell states (Figs. S1-S6, videos S1-S4). These materials are available free of charge at http://pubs.acs.org.

ACKNOWLEDGMENT This work was supported by ARC Project No. CE140100036 (Davis), ARC Centre of Excellence Scheme Project No. CE 140100012 (Higgins), NSF CAREER CBET-1553945 (Ding), NIH MIRA R35GM119691 (Ding) and AFTAM Research Collaboration Award (Davis and Ke). TEM imaging was performed at Bio21 Advanced Microscopy Facility, the University of Melbourne. STED imaging was performed at the Monash Micro Imaging Facility, Monash University. XDR was performed at the X-ray Diffraction Facility, the University of Melbourne. The Australian Regenerative Medicine Institute is supported by grants from the State Government of Victoria and the Australian federal government. The authors wish to thank Dr. Robert W. Gable for help with XRD and Dr. Alex Fulcher for help with STED, and AquaCore, Monash University for microscope access and support with fish husbandry.

Competing financial interests: The authors declare no conflicting financial interests.

Author contributions PCK, AK and TPD designed the project. AK performed TEM imaging and AF conducted FiberApp data analysis. AK, NHA, LF and MJH performed HS-AFM imaging and AK


Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

conducted data analyses. IJ and AK performed STED imaging and XRD. YX, YS and FD conducted DMD, atomistic and CG simulations and analyses. AK, AF, AMD and JK conducted zebrafish embryo toxicity assays. AK, PCK, YX and FD wrote the paper. All authors agreed on the presentation of the manuscript.


Page 16 of 28

Page 17 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

Figures and Captions

Scheme 1. Techniques employed for characterizing the hetero-amyloidosis of IAPP with its amyloidogenic fragments IAPP8-20 and 19-29 S20G and their in vivo application with a zebrafish model. ThT: thioflavin T kinetic assay. TEM: transmission electron microscopy. Confocal: confocal fluorescence microscopy. STED: Stimulated emission depletion microscopy. XRD: X-ray diffraction spectroscopy. DMD: discrete molecular dynamics simulations. HS-AFM: high-speed atomic force microscopy.


Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 1. Effects of fragments on IAPP fibril aggregation. Panel D was derived from the ThT assay, while panels E and F were calculated from computer simulations. (A) Amino acid sequences of fulllength human IAPP (37 residues), 19-29 S20G and 8-20 fragments. Red residue in the 19-29 S20G fragment sequence shows the early onset S20G familial mutation. (B) ThT assay revealed significantly promoted aggregation rate of IAPP in presence of 19-29 S20G. (C) 8-20 fragments promoted IAPP aggregation comparably to full-length IAPP. (D) Lag time derived from analysis of ThT fluorescence curves. * denotes statistically significant differences between sample mean to a control mean (ANOVA; * P ≤ 0.05; *** P ≤ 0.005). (E) A coarse-grained peptide model with different barriers between π-state (representing random-coil or helix) and β-state (representing β-sheet) was used in the simulation, where the two states were shown in the inset with stick representation. (F) The number of β-sheets was calculated for each simulation system and plotted as a function of simulation time (IAPP + IAPP corresponds to 2× IAPP concentration).


Page 18 of 28

Page 19 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

Figure 2. Effects of fragments on IAPP fibril morphology. Panels A-L were acquired from TEM, confocal and STED imaging as well as X-ray diffraction, panels M-O were obtained from computer simulations, and panels P-S are cartoon representations of IAPP-fragment hetero-amyloids. (A) IAPP fibril and IAPP co-aggregated with (B) 19-29 S20G and (C) 8-20 at equimolar concentration of 25 µM over 24 h at room temperature. Red dotted line charts represent periodicity analysis of twisted fibril using grayscale histogram plotting along the fibril axis (white arrows indicate the analyzed fibrils). (D-F) Confocal fluorescence microscopy of a ThT-labelled IAPP fibril, a ThT-labelled IAPP + 19-29 S20G co-aggregated fibril, and a ThT labelled IAPP + 8-20 co-aggregated fibril, respectively. (G-I) Stimulated emission depletion (STED) super-resolution microscopy of IAPP fibrils with and w/o the fragments confirmed co-aggregation of (G) non-labelled IAPP with Alexa 647-labelled (H) 19-29 S20G and (I) 8-20 fragments into single hetero-peptide fibrils. X-ray diffraction pattern of (J) IAPP, (K) IAPP + 19-29 S20G and (L) IAPP + 8-20 amyloids. (M) The double U-shape model of an IAPP fibril representing two IAPP molecules mated into a steric zipper around the fibril axis. 8-20 and 19-29 amino-acid sections are highlighted in purple and orange, respectively. Possible binding sites of (N) 1929 S20G (orange) and (O) 8-20 (purple) fragments to full-length fibril (grey) during fibrillization based on the complementarity of amino-acid sequences. Schematic peptide arrangements in homogeneous (P) IAPP fibril and heterogeneous (R) IAPP + 19-29 S20G and (S) IAPP + 8-20 fibrils, where the grey rectangles represent full-length IAPP, orange 19-29 S20G fragments, and purple 8-20 fragments.


Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 3. Effects of fragments on single IAPP fibril elongation revealed by high-speed atomic force microscopy (HS-AFM). HS-AFM images during IAPP fibrillization (A) without and with (B) 19-29 S20G and (C) 8-20 fragments indicated increased formation of small aggregates in heterogeneous samples. (D) Fibril height histogram (n = 35, 68 and 42 for IAPP, IAPP + 19-29 S20G and IAPP + 820, respectively). White dotted lines in panels A-C represent high line profiles presented in panels E, F and G. Representative kymographs of (H) pure IAPP, (I) IAPP + 19-29 S20G and (J) IAPP + 8-20 fibril elongation. (K) Time-lapse AFM images (also see video S4) of simultaneous co-elongation of (L) bundled protofibrils (IAPP + 19-29 S20G) and (M) relevant height profiles.


Page 20 of 28

Page 21 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

Figure 4. A quantitative analysis of single fibril elongation assay. Panels A, C, E, F, G and H were derived from HS-AFM experiments, while panels B and D were obtained from computer simulations. (A) Elongation rate constant. Apparent elongation rates obtained from the final fibril length measurements at the end of the elongation assay (Fig. S4A). (B) The number of peptides in one fibril as a function of simulation time, where the initial simulation state and final state are shown in the insets. The fibril growth exhibited two states, namely, elongation state and dwell state, marked by the solid and dashed arrows, separately. (C) The rate of pause-free elongation indicates underestimation of the fibril elongation rate which arise from growth intermittency (n = 19, 14 and 28 for IAPP, IAPP + 1929 S20G and IAPP + 8-20, respectively) (see Figs. S3,4). (D) The apparent elongation rates were obtained from the linear fitting of multiple fibril growths in panel B. Typical snapshots of fibril structures are shown in the insets. (E-H) Statistical analysis of stepwise IAPP fibril growth or IAPP coaggregated with the fragments: (E) dwell (pause) time (n = 16, 12 and 22 for IAPP, IAPP + 19-29 S20G and IAPP + 8-20, respectively), (F) step time (n = 19, 14 and 28 for IAPP, IAPP + 19-29 S20G and IAPP + 8-20, respectively), and (G) step size (n = 19, 14 and 28 for IAPP, IAPP + 19-29 S20G and IAPP + 8-20, respectively). (H) Correlation between step size and step time. Error bars denote the mean ± SD. * denotes statistically significant differences between sample mean to a control mean (ANOVA; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.005; **** P ≤ 0.001).


Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 5. Determination of in vivo toxicity of IAPP with or without the fragments by the zebrafish embryo toxicity assay. Rates of (A) survival, (B) hatching and (C) developmental abnormalities of zebrafish embryos were qualified until 72 h after administration of treatments (related to fully hatched, untreated embryos) by microinjection of 1 nL of 5 µM IAPP with or without 19-28 S20G and 8-20 fragments into the chorion of 2 h post fertilisation (hpf) embryos. (D) Representative images of embryonic development (0-72 hpf), dead, unhatched and phenotypically abnormal embryos. Assays were carried out in triplicate. Error bars show the standard deviations of the averaged data sets (*: P ≤ 0.05, **: P ≤ 0.01, ****: P ≤ 0.001).


Page 22 of 28

Page 23 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

REFERENCES (1) (2) (3) (4) (5) (6)

(7) (8) (9) (10) (11) (12) (13) (14)

(15) (16)

Ke, P. C.; Sani, M.-A.; Ding, F.; Kakinen, A.; Javed, I.; Separovic, F.; Davis, T. P.; Mezzenga, R. Implications of peptide assemblies in amyloid diseases. Chem. Soc. Rev. 2017, 46, 6492-6531. Sunde, M.; Serpell, L. C.; Bartlam, M.; Fraser, P. E.; Pepys, M. B.; Blake, C. C. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 1997, 273, 729-739. Adamcik, J.; Mezzenga, R. Amyloid polymorphism in the protein folding and aggregation energy landscape. Angew. Chem. Int. Ed. 2018, 57, 8370-8382. Palhano, F. L.; Lee, J.; Grimster, N. P.; Kelly, J. W. Toward the molecular mechanism (s) by which EGCG treatment remodels mature amyloid fibrils. J. Am. Chem. Soc. 2013, 135, 7503-7510. Hoyer, W.; Cherny, D.; Subramaniam, V.; Jovin, T. M. Rapid self-assembly of αsynuclein observed by in situ atomic force microscopy. J. Mol. Biol. 2004, 340 (1), 127139. Zhang, S.; Andreasen, M.; Nielsen, J. T.; Liu, L.; Nielsen, E. H.; Song, J.; Ji, G.; Sun, F.; Skrydstrup, T.; Besenbacher, F. Coexistence of ribbon and helical fibrils originating from hIAPP20–29 revealed by quantitative nanomechanical atomic force microscopy. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 2798-2803. Milhiet, P.-E.; Yamamoto, D.; Berthoumieu, O.; Dosset, P.; Le Grimellec, C.; Verdier, J.-M.; Marchal, S.; Ando, T. Deciphering the structure, growth and assembly of amyloidlike fibrils using high-speed atomic force microscopy. PLoS One 2010, 5, e13240. Banerjee, S.; Sun, Z.; Hayden, E. Y.; Teplow, D. B.; Lyubchenko, Y. L. Nanoscale dynamics of amyloid β-42 oligomers as revealed by high-speed atomic force microscopy. ACS Nano 2017, 11, 12202-12209. Doherty, C. P.; Young, L. M.; Karamanos, T. K.; Smith, H. I.; Jackson, M. P.; Radford, S. E.; Brockwell, D. J. A peptide‐display protein scaffold to facilitate single molecule force studies of aggregation‐prone peptides. Protein Sci. 2018, 27, 1205-1217. Zhu, M.; Souillac, P. O.; Ionescu-Zanetti, C.; Carter, S. A.; Fink, A. L. Surface-catalyzed amyloid fibril formation. J. Biol. Chem. 2002, 277, 50914-50922. Campioni, S.; Carret, G.; Jordens, S.; Nicoud, L. C.; Mezzenga, R.; Riek, R. The presence of an air–water interface affects formation and elongation of α-synuclein fibrils. J. Am. Chem. Soc. 2014, 136, 2866-2875. Ruggeri, F. S.; Šneideris, T.; Vendruscolo, M.; Knowles, T. P. Atomic force microscopy for single molecule characterisation of protein aggregation. Arch. Biochem. Biophys. 2019, 664, 134-148. Knowles, T. P.; Waudby, C. A.; Devlin, G. L.; Cohen, S. I.; Aguzzi, A.; Vendruscolo, M.; Terentjev, E. M.; Welland, M. E.; Dobson, C. M. An analytical solution to the kinetics of breakable filament assembly. Science 2009, 326, 1533-1537. Cohen, S. I.; Linse, S.; Luheshi, L. M.; Hellstrand, E.; White, D. A.; Rajah, L.; Otzen, D. E.; Vendruscolo, M.; Dobson, C. M.; Knowles, T. P. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 9758-9763. Bernis, M. E.; Babila, J. T.; Breid, S.; Wüsten, K. A.; Wüllner, U.; Tamgüney, G. Prionlike propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol. Commun. 2015, 3, 75. Paul, A.; Nadimpally, K. C.; Mondal, T.; Thalluri, K.; Mandal, B. Inhibition of Alzheimer's amyloid-β peptide aggregation and its disruption by a conformationally restricted α/β hybrid peptide. Chem. Comm. 2015, 51, 2245-2248. 23 ACS Paragon Plus Environment

Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(17) Kakinen, A.; Javed, I.; Faridi, A.; Davis, T. P.; Ke, P. C. Serum albumin impedes the amyloid aggregation and hemolysis of human islet amyloid polypeptide and alpha synuclein. BBA Biomembrane 2018, 1860, 1803-1809. (18) Pilkington, E. H.; Lai, M.; Ge, X.; Stanley, W. J.; Wang, B.; Wang, M.; Kakinen, A.; Sani, M.-A.; Whittaker, M. R.; Gurzov, E. N.; Ding, F.; Quinn, J. F.; Davis, T. P.; Ke, P. C. Star polymers reduce islet amyloid polypeptide toxicity via accelerated amyloid aggregation. Biomacromolecules 2017, 18, 4249-4260. (19) Krotee, P.; Rodriguez, J. A.; Sawaya, M. R.; Cascio, D.; Reyes, F. E.; Shi, D.; Hattne, J.; Nannenga, B. L.; Oskarsson, M. E.; Philipp, S. Atomic structures of fibrillar segments of hIAPP suggest tightly mated β-sheets are important for cytotoxicity. elife 2017, 6, e19273. (20) Soto, C.; Sigurdsson, E. M.; Morelli, L.; Kumar, R. A.; Castaño, E. M.; Frangione, B. βsheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 1998, 4, 822. (21) Dong, J.; Canfield, J. M.; Mehta, A. K.; Shokes, J. E.; Tian, B.; Childers, W. S.; Simmons, J. A.; Mao, Z.; Scott, R. A.; Warncke, K. Engineering metal ion coordination to regulate amyloid fibril assembly and toxicity. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 13313-13318. (22) Viles, J. H. Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, zinc and iron in Alzheimer's, Parkinson's and prion diseases. Coord. Chem. Rev. 2012, 256, 2271-2284. (23) Del Barrio, M.; Borghesani, V.; Hureau, C.; Faller, P. Metal-binding to amyloid-β peptide: coordination, aggregation, and reactive oxygen species production. Biometals in Neurodegenerative Diseases 2017, 265-281. (24) Lansbury, P. T.; Lashuel, H. A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006, 443, 774. (25) Doody, R. S.; Thomas, R. G.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; Raman, R.; Sun, X.; Aisen, P. S. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370, 311-321. (26) Salloway, S.; Sperling, R.; Fox, N. C.; Blennow, K.; Klunk, W.; Raskind, M.; Sabbagh, M.; Honig, L. S.; Porsteinsson, A. P.; Ferris, S. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370, 322-333. (27) Bieschke, J.; Herbst, M.; Wiglenda, T.; Friedrich, R. P.; Boeddrich, A.; Schiele, F.; Kleckers, D.; del Amo, J. M. L.; Grüning, B. A.; Wang, Q. Small-molecule conversion of toxic oligomers to nontoxic β-sheet–rich amyloid fibrils. Nat. Chem. Biol. 2012, 8, 93. (28) Kakinen, A.; Adamcik, J.; Wang, B.; Ge, X.; Mezzenga, R.; Davis, T. P.; Ding, F.; Ke, P. C. Nanoscale inhibition of polymorphic and ambidextrous IAPP amyloid aggregation with small molecules. Nano Res. 2018, 11, 3636-3647. (29) Cao, P.; Raleigh, D. P. Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols. Biochemistry 2012, 51, 2670-2683. (30) Nedumpully-Govindan, P.; Kakinen, A.; Pilkington, E. H.; Davis, T. P.; Ke, P. C.; Ding, F. Stabilizing off-pathway oligomers by polyphenol nanoassemblies for IAPP aggregation inhibition. Sci. Rep. 2016, 6, 19463. (31) Sahoo, B. R.; Genjo, T.; Moharana, K. C.; Ramamoorthy, A. Self-assembly of polymerencased lipid nanodiscs and membrane protein reconstitution. J. Phys. Chem. B 2019, 123, 4562-4570. (32) Ke, P. C.; Pilkington, E. H.; Sun, Y.; Javed, I.; Kakinen, A.; Peng, G.; Ding, F.; Davis, T. P. Mitigation of amyloidosis with nanomaterials. Adv. Mater. 2019, 1901690. (33) Castle, B. T.; Odde, D. J.; Wood, D. K. Rapid and inefficient kinetics of sickle hemoglobin fiber growth. Sci. Adv. 2019, 5, eaau1086. 24 ACS Paragon Plus Environment

Page 24 of 28

Page 25 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

(34) Sahoo, B. R.; Genjo, T.; Cox, S. J.; Stoddard, A. K.; Anantharamaiah, G. M.; Fierke, C.; Ramamoorthy, A. Nanodisc-forming scaffold protein promoted retardation of amyloidbeta aggregation. J. Mol. Biol. 2018, 430, 4230-4244. (35) Viennet, T.; Wördehoff, M. M.; Uluca, B.; Poojari, C.; Shaykhalishahi, H.; Willbold, D.; Strodel, B.; Heise, H.; Buell, A. K.; Hoyer, W.; Etzkorn, M. Structural insights from lipid-bilayer nanodiscs link α-Synuclein membrane-binding modes to amyloid fibril formation. Commun. Biol. 2018, 1, 44. (36) Kim, D.; Yoo, J. M.; Hwang, H.; Lee, J.; Lee, S. H.; Yun, S. P.; Park, M. J.; Lee, M.; Choi, S.; Kwon, S. H.; Lee, S.; Kwon, S.-H.; Kim, S.; Park, Y. J.; Kinoshita, M.; Lee, Y.-H.; Shin, S.; Paik, S. R.; Lee, S. J.; Lee, S.; Hong, B. H.; Ko, H. S. Graphene quantum dots prevent α-synucleinopathy in Parkinson’s disease. Nat. Nano. 2018, 13, 812-818. (37) Luo, Q.; Lin, Y.-X.; Yang, P.-P.; Wang, Y.; Qi, G.-B.; Qiao, Z.-Y.; Li, B.-N.; Zhang, K.; Zhang, J.-P.; Wang, L.; Wang, H. A self-destructive nanosweeper that captures and clears amyloid β-peptides. Nat. Comm. 2018, 9, 1802. (38) Chen, Q.; Du, Y.; Zhang, K.; Liang, Z.; Li, J.; Yu, H.; Ren, R.; Feng, J.; Jin, Z.; Li, F. Tau-targeted multifunctional nanocomposite for combinational therapy of Alzheimer’s disease. ACS Nano 2018, 12, 1321-1338. (39) Gladytz, A.; Abel, B.; Risselada, H. J. Gold‐induced fibril growth: The mechanism of surface‐facilitated amyloid aggregation. Angew. Chem. Int. Ed. 2016, 55, 11242-11246. (40) Gurzov, E. N.; Wang, B.; Pilkington, E. H.; Chen, P.; Kakinen, A.; Stanley, W. J.; Litwak, S. A.; Hanssen, E. G.; Davis, T. P.; Ding, F. Inhibition of hIAPP amyloid aggregation and pancreatic β‐cell toxicity by OH‐terminated PAMAM dendrimer. Small 2016, 12, 1615-1626. (41) Mahmoudi, M.; Akhavan, O.; Ghavami, M.; Rezaee, F.; Ghiasi, S. M. A. Graphene oxide strongly inhibits amyloid beta fibrillation. Nanoscale 2012, 4, 7322-7325. (42) Faridi, A.; Sun, Y.; Okazaki, Y.; Peng, G.; Gao, J.; Kakinen, A.; Faridi, P.; Zhao, M.; Javed, I.; Purcell, A. W.; Davis, T. P.; Lin, S.; Reiko, O.; Ding, F.; Ke, P. C. Mitigating human IAPP amyloidogenesis in vivo with chiral silica nanoribbons. Small 2018, 14, 1802825. (43) Javed, I.; Yu, T.; Peng, G.; Sánchez-Ferrer, A.; Faridi, A.; Kakinen, A.; Zhao, M.; Mezzenga, R.; Davis, T. P.; Lin, S.; Ke, P. C. In vivo mitigation of amyloidogenesis through functional–pathogenic double-protein coronae. Nano Lett. 2018, 18, 5797-5804. (44) Wang, M.; Sun, Y.; Cao, X.; Peng, G.; Javed, I.; Kakinen, A.; Davis, T. P.; Lin, S.; Liu, J.; Ding, F.; Ke, P. C. Graphene quantum dots against human IAPP aggregation and toxicity in vivo. Nanoscale 2018, 10, 19995-20006. (45) Scrocchi, L. A.; Chen, Y.; Waschuk, S.; Wang, F.; Cheung, S.; Darabie, A. A.; McLaurin, J.; Fraser, P. E. Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis. J. Mol. Biol. 2002, 318, 697-706. (46) Padrick, S. B.; Miranker, A. D. Islet amyloid polypeptide: identification of long-range contacts and local order on the fibrillogenesis pathway. J. Mol. Biol. 2001, 308, 783-794. (47) Tenidis, K.; Waldner, M.; Bernhagen, J.; Fischle, W.; Bergmann, M.; Weber, M.; Merkle, M.-L.; Voelter, W.; Brunner, H.; Kapurniotu, A. Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J. Mol. Biol. 2000, 295, 1055-1071. (48) Meier, D. T.; Entrup, L.; Templin, A. T.; Hogan, M. F.; Mellati, M.; Zraika, S.; Hull, R. L.; Kahn, S. E. The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets. Diabetologia 2016, 59, 2166-2171. (49) Sakagashira, S.; Hiddinga, H. J.; Tateishi, K.; Sanke, T.; Hanabusa, T.; Nanjo, K.; Eberhardt, N. L. S20G Mutant amylin exhibits increased in vitro amyloidogenicity and


Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60)

(61)

(62)

(63) (64) (65)

increased intracellular cytotoxicity compared to wild-type amylin. Am. J. Pathol. 2000, 157, 2101-2109. Abedini, A.; Meng, F.; Raleigh, D. P. A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor. J. Am. Chem. Soc. 2007, 129, 11300-11301. Scrocchi, L. A.; Ha, K.; Chen, Y.; Wu, L.; Wang, F.; Fraser, P. E. Identification of minimal peptide sequences in the (8–20) domain of human islet amyloid polypeptide involved in fibrillogenesis. J. Struct. Biol. 2003, 141, 218-227. Jaikaran, E. T. A. S.; Higham, C. E.; Serpell, L. C.; Zurdo, J.; Gross, M.; Clark, A.; Fraser, P. E. Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 2001, 308, 515-525. Goldsbury, C. S.; Cooper, G. J. S.; Goldie, K. N.; Müller, S. A.; Saafi, E. L.; Gruijters, W. T. M.; Misur, M. P.; Engel, A.; Aebi, U.; Kistler, J. Polymorphic fibrillar assembly of human amylin. J. Struct. Biol. 1997, 119, 17-27. Powers, E. T.; Powers, D. L. The kinetics of nucleated polymerizations at high concentrations: amyloid fibril formation near and above the “supercritical concentration”. Biophys. J. 2006, 91, 122-132. Hong, L.; Yong, W.-A. Simple moment-closure model for the self-assembly of breakable amyloid filaments. Biophys. J. 2013, 104, 533-540. Gillam, J. E.; MacPhee, C. E. Modelling amyloid fibril formation kinetics: mechanisms of nucleation and growth. J. Phys. Condens. Matter 2013, 25, 373101. Cohen, S. I. A.; Vendruscolo, M.; Welland, M. E.; Dobson, C. M.; Terentjev, E. M.; Knowles, T. P. J. Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments. J. Chem. Phys. 2011, 135, 065105. Ma, Z.; Westermark, G. T.; Sakagashira, S.; Sanke, T.; Gustavsson, Å.; Sakamoto, H.; Engström, U.; Nanjo, K.; Westermark, P. Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide. Amyloid 2001, 8, 242-249. Wang, L.; Ilitchev, A. I.; Giammona, M. J.; Li, F.; Buratto, S. K.; Bowers, M. T. Human islet amyloid polypeptide assembly: The key role of the 8–20 fragment. J. Phys. Chem. B 2016, 120, 11905-11911. Sun, Y.; Kakinen, A.; Xing, Y.; Faridi, P.; Nandakumar, A.; Purcell, A. W.; Davis, T. P.; Ke, P. C.; Ding, F. Amyloid self-assembly of hiapp8-20 via the accumulation of helical oligomers, α-helix to β-sheet transition, and formation of β-barrel intermediates. Small 2019, 15, 1805166. Gordon, D. J.; Sciarretta, K. L.; Meredith, S. C. Inhibition of β-amyloid(40) fibrillogenesis and disassembly of β-amyloid(40) fibrils by short β-amyloid congeners containing n-methyl amino acids at alternate residues. Biochemistry 2001, 40, 82378245. Findeis, M. A.; Musso, G. M.; Arico-Muendel, C. C.; Benjamin, H. W.; Hundal, A. M.; Lee, J.-J.; Chin, J.; Kelley, M.; Wakefield, J.; Hayward, N. J.; Molineaux, S. M. Modified-peptide inhibitors of amyloid β-peptide polymerization. Biochemistry 1999, 38, 6791-6800. Tjernberg, L. O.; Näslund, J.; Lindqvist, F.; Johansson, J.; Karlström, A. R.; Thyberg, J.; Terenius, L.; Nordstedt, C. Arrest of amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 1996, 271, 8545-8548. Andrews, M. N.; Winter, R. Comparing the structural properties of human and rat islet amyloid polypeptide by MD computer simulations. Biophys. Chem. 2011, 156, 43-50. Sun, Y.; Kakinen, A.; Xing, Y.; Pilkington, E. H.; Davis, T. P.; Ke, P. C.; Ding, F. Nucleation of β-rich oligomers and β-barrels in the early aggregation of human islet amyloid polypeptide. BBA Mol. Basis Dis. 2019, 1865, 434-444. 26 ACS Paragon Plus Environment

Page 26 of 28

Page 27 of 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nano Letters

(66) Bai, C.; Lin, D.; Mo, Y.; Lei, J.; Sun, Y.; Xie, L.; Yang, X.; Wei, G. Influence of fullerenol on hIAPP aggregation: amyloid inhibition and mechanistic aspects. Phys. Chem. Chem. Phys. 2019, 21, 4022-4031. (67) Dupuis, N. F.; Wu, C.; Shea, J.-E.; Bowers, M. T. The amyloid formation mechanism in human IAPP: dimers have β-strand monomer-monomer interfaces. J. Am. Chem. Soc. 2011, 133, 7240-7243. (68) Mo, Y.; Lei, J.; Sun, Y.; Zhang, Q.; Wei, G. Conformational ensemble of hIAPP dimer: Insight into the molecular mechanism by which a green tea extract inhibits hIAPP aggregation. Sci. Rep. 2016, 6, 33076. (69) Laghaei, R.; Mousseau, N.; Wei, G. Structure and thermodynamics of amylin dimer studied by hamiltonian-temperature replica exchange molecular dynamics simulations. J. Phys. Chem. B 2011, 115, 3146-3154. (70) Cohen, S. I. A.; Vendruscolo, M.; Dobson, C. M.; Knowles, T. P. J. From macroscopic measurements to microscopic mechanisms of protein aggregation. J. Mol. Biol. 2012, 421, 160-171. (71) Arosio, P.; Cukalevski, R.; Frohm, B.; Knowles, T. P. J.; Linse, S. Quantification of the concentration of Aβ42 propagons during the lag phase by an amyloid chain reaction assay. J. Am. Chem. Soc. 2014, 136, 219-225. (72) Huang, Q.; Wang, H.; Gao, H.; Cheng, P.; Zhu, L.; Wang, C.; Yang, Y. In situ observation of amyloid nucleation and fibrillation by fastscan atomic force microscopy. J. Phys. Chem. Lett. 2019, 10, 214-222. (73) Watanabe-Nakayama, T.; Ono, K.; Itami, M.; Takahashi, R.; Teplow, D. B.; Yamada, M. High-speed atomic force microscopy reveals structural dynamics of amyloid β1–42 aggregates. Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 5835-5840. (74) Kellermayer, M. S. Z.; Karsai, Á.; Benke, M.; Soós, K.; Penke, B. Stepwise dynamics of epitaxially growing single amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 141144. (75) Ban, T.; Hoshino, M.; Takahashi, S.; Hamada, D.; Hasegawa, K.; Naiki, H.; Goto, Y. Direct observation of Aβ amyloid fibril growth and inhibition. J. Mol. Biol. 2004, 344, 757-767. (76) Young, L. J.; Kaminski Schierle, G. S.; Kaminski, C. F. Imaging Aβ(1–42) fibril elongation reveals strongly polarised growth and growth incompetent states. Phys. Chem. Chem. Phys. 2017, 19, 27987-27996. (77) Zhang, Y.; Hashemi, M.; Lv, Z.; Williams, B.; Popov, K. I.; Dokholyan, N. V.; Lyubchenko, Y. L. High-speed atomic force microscopy reveals structural dynamics of α-synuclein monomers and dimers. J. Chem. Phys. 2018, 148, 123322. (78) Wiltzius, J. J. W.; Sievers, S. A.; Sawaya, M. R.; Cascio, D.; Popov, D.; Riekel, C.; Eisenberg, D. Atomic structure of the cross-β spine of islet amyloid polypeptide (amylin). Protein Sci. 2008, 17, 1467-1474. (79) Luca, S.; Yau, W.-M.; Leapman, R.; Tycko, R. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry 2007, 46, 13505-13522. (80) Tycko, R. Molecular structure of amyloid fibrils: insights from solid-state NMR. Q. Rev. Biophys. 2006, 39, 1-55. (81) Chen, B.; Thurber, K. R.; Shewmaker, F.; Wickner, R. B.; Tycko, R. Measurement of amyloid fibril mass-per-length by tilted-beam transmission electron microscopy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 14339-14344. (82) Lin, S.; Zhao, Y.; Nel, A. E.; Lin, S. Zebrafish: an in vivo model for nano EHS studies. Small 2013, 9, 1608-1618.


Nano Letters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(83) Kalueff, A. V.; Stewart, A. M.; Gerlai, R. Zebrafish as an emerging model for studying complex brain disorders. Trends Pharmacol. Sci. 2014, 35, 63-75. (84) Best, J. D.; Alderton, W. K. Zebrafish: An in vivo model for the study of neurological diseases. Neuropsych. Dis. Treat. 2008, 4, 567-576. (85) Kakinen, A.; Sun, Y.; Javed, I.; Faridi, A.; Pilkington, E. H.; Faridi, P.; Purcell, A. W.; Zhou, R.; Ding, F.; Lin, S.; Ke, P. C.; Davis, T. P. Physical and toxicological profiles of human IAPP amyloids and plaques. Sci. Bull. 2019, 64, 26-35. (86) Kahn, S. E.; Andrikopoulos, S.; Verchere, C. B. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999, 48, 241-253. (87) Keten, S.; Xu, Z.; Ihle, B.; Buehler, M. J. Nanoconfinement controls stiffness, strength and mechanical toughness of β-sheet crystals in silk. Nat. Mat. 2010, 9, 359. (88) Javed, I.; Peng, G.; Xing, Y.; Yu, T.; Zhao, M.; Kakinen, A.; Faridi, A.; Parish, C. L.; Ding, F.; Davis, T. P.; Ke, P. C.; Lin, S. Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy. Nat. Comm. 2019, 10, 3780.

Table of Content Graphic


Page 28 of 28

Single-Molecular Heteroamyloidosis of Human Islet Amyloid Polypeptide

Recommend Documents